ORGANOGENESIS HOLDINGS INC. Increase (Decrease) in Accounts Receivable
ORGANOGENESIS HOLDINGS INC. (ORGO) reported Increase (Decrease) in Accounts Receivable of -$119.49 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsReceivable · last filed 2026-08-06
- ORGANOGENESIS HOLDINGS INC. increase (decrease) in accounts receivable for the quarter ending 2026-06-30 was -$14.99M, a 177.63% decline year-over-year.
- ORGANOGENESIS HOLDINGS INC. increase (decrease) in accounts receivable for the quarter ending 2026-03-31 was -$104.50M.
- ORGANOGENESIS HOLDINGS INC. increase (decrease) in accounts receivable for the quarter ending 2025-12-31 was $51.48M, a 484.71% increase year-over-year.
- ORGANOGENESIS HOLDINGS INC. increase (decrease) in accounts receivable for the quarter ending 2025-09-30 was $50.69M.
- ORGANOGENESIS HOLDINGS INC. increase (decrease) in accounts receivable for fiscal 2025 was $115.80M, a 264.16% increase from fiscal 2024.
- ORGANOGENESIS HOLDINGS INC. increase (decrease) in accounts receivable for fiscal 2024 was $31.80M.
- ORGANOGENESIS HOLDINGS INC. increase (decrease) in accounts receivable for fiscal 2023 was -$5.54M, a 163.16% decline from fiscal 2022.
- ORGANOGENESIS HOLDINGS INC. increase (decrease) in accounts receivable for fiscal 2022 was $8.77M, a 69.39% decline from fiscal 2021.
| Period end | Increase (Decrease) in Accounts Receivable 3 month | Increase (Decrease) in Accounts Receivable 3 month as first filed | Increase (Decrease) in Accounts Receivable 6 month | Increase (Decrease) in Accounts Receivable 6 month as first filed | Increase (Decrease) in Accounts Receivable 9 month | Increase (Decrease) in Accounts Receivable 9 month as first filed | Increase (Decrease) in Accounts Receivable 12 month | Increase (Decrease) in Accounts Receivable 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$14.99M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$119.49M 10-Q · filed 2026-08-06 | -$68.01M derived: sum of 3 quarters · filed 2026-08-06 | -$17.32M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2026-03-31 | -$104.50M 10-Q · filed 2026-05-07 | -$53.02M derived: sum of 2 quarters · filed 2026-05-07 | -$2.34M derived: sum of 3 quarters · filed 2026-05-07 | $16.97M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-12-31 | $51.48M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $102.17M derived: sum of 2 quarters · filed 2026-02-26 | $121.47M derived: sum of 3 quarters · filed 2026-08-06 | $115.80M 10-K · filed 2026-02-26 | ||||
| 2025-09-30 | $50.69M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $69.99M derived: sum of 2 quarters · filed 2026-08-06 | $64.33M 10-Q · filed 2025-11-06 | $73.13M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-06-30 | $19.30M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $13.64M 10-Q · filed 2026-08-06 | $22.44M derived: sum of 3 quarters · filed 2026-08-06 | $19.46M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-03-31 | -$5.67M 10-Q · filed 2026-05-07 | $3.14M derived: sum of 2 quarters · filed 2026-05-07 | $154.00K derived: sum of 3 quarters · filed 2026-05-07 | $11.02M derived: sum of 4 quarters · filed 2026-05-07 | ||||
| 2024-12-31 | $8.80M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $5.82M derived: sum of 2 quarters · filed 2026-02-26 | $16.68M derived: sum of 3 quarters · filed 2026-02-26 | $31.80M 10-K · filed 2026-02-26 | ||||
| 2024-09-30 | -$2.98M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $7.88M derived: sum of 2 quarters · filed 2025-11-06 | $23.00M 10-Q · filed 2025-11-06 | $15.70M derived: sum of 4 quarters · filed 2026-02-26 | ||||
| 2024-06-30 | $10.86M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $25.98M 10-Q · filed 2025-08-07 | $18.68M derived: sum of 3 quarters · filed 2026-02-26 | $15.47M derived: sum of 4 quarters · filed 2026-02-26 | ||||
| 2024-03-31 | $15.12M 10-Q · filed 2025-05-08 | $7.82M derived: sum of 2 quarters · filed 2026-02-26 | $4.61M derived: sum of 3 quarters · filed 2026-02-26 | $6.15M derived: sum of 4 quarters · filed 2026-02-26 | ||||
| 2023-12-31 | -$7.30M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$10.51M derived: sum of 2 quarters · filed 2026-02-26 | -$8.97M derived: sum of 3 quarters · filed 2026-02-26 | -$5.54M 10-K · filed 2026-02-26 | ||||
| 2023-09-30 | -$3.21M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | -$1.67M derived: sum of 2 quarters · filed 2024-11-12 | $1.76M 10-Q · filed 2024-11-12 | -$979.00K derived: sum of 4 quarters · filed 2025-02-27 | ||||
| 2023-06-30 | $1.54M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $4.97M 10-Q · filed 2024-08-08 | $2.23M derived: sum of 3 quarters · filed 2025-02-27 | $7.25M derived: sum of 4 quarters · filed 2025-02-27 | ||||
| 2023-03-31 | $3.43M 10-Q · filed 2024-05-09 | $689.00K derived: sum of 2 quarters · filed 2025-02-27 | $5.71M derived: sum of 3 quarters · filed 2025-02-27 | $15.14M derived: sum of 4 quarters · filed 2025-02-27 | ||||
| 2022-12-31 | -$2.74M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $2.29M derived: sum of 2 quarters · filed 2025-02-27 | $11.71M derived: sum of 3 quarters · filed 2025-02-27 | $8.77M 10-K · filed 2025-02-27 | ||||
| 2022-09-30 | $5.03M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $14.45M derived: sum of 2 quarters · filed 2023-11-09 | $11.51M 10-Q · filed 2023-11-09 | $20.02M derived: sum of 4 quarters · filed 2024-02-29 | ||||
| 2022-06-30 | $9.43M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | $6.49M 10-Q · filed 2023-08-09 | $14.99M derived: sum of 3 quarters · filed 2024-02-29 | $13.68M derived: sum of 4 quarters · filed 2024-02-29 | ||||
| 2022-03-31 | -$2.94M 10-Q · filed 2023-05-10 | $5.57M derived: sum of 2 quarters · filed 2024-02-29 | $4.25M derived: sum of 3 quarters · filed 2024-02-29 | $9.59M derived: sum of 4 quarters · filed 2024-02-29 | ||||
| 2021-12-31 | $8.51M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $7.19M derived: sum of 2 quarters · filed 2024-02-29 | $12.54M derived: sum of 3 quarters · filed 2024-02-29 | $28.65M 10-K · filed 2024-02-29 | ||||
| 2021-09-30 | -$1.31M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $4.03M derived: sum of 2 quarters · filed 2022-11-09 | $20.15M 10-Q · filed 2022-11-09 | $20.64M 10-Q · filed 2021-11-09 | $18.55M derived: sum of 4 quarters · filed 2023-03-01 | |||
| 2021-06-30 | $5.34M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $21.46M 10-Q · filed 2022-08-09 | $22.12M 10-Q · filed 2021-08-09 | $19.87M derived: sum of 3 quarters · filed 2023-03-01 | $33.30M derived: sum of 4 quarters · filed 2023-03-01 | |||
| 2021-03-31 | $16.12M 10-Q · filed 2022-05-10 | $16.30M 10-Q · filed 2021-05-11 | $14.53M derived: sum of 2 quarters · filed 2023-03-01 | $27.96M derived: sum of 3 quarters · filed 2023-03-01 | $40.01M derived: sum of 4 quarters · filed 2023-03-01 | |||
| 2020-12-31 | -$1.59M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | $11.84M derived: sum of 2 quarters · filed 2023-03-01 | $23.89M derived: sum of 3 quarters · filed 2023-03-01 | $17.57M 10-K · filed 2023-03-01 | $18.82M 10-K · filed 2021-03-16 | |||
| 2020-09-30 | $13.43M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | $25.48M derived: sum of 2 quarters · filed 2021-11-09 | $19.16M 10-Q · filed 2021-11-09 | $24.40M derived: sum of 4 quarters · filed 2022-03-01 | ||||
| 2020-06-30 | $12.05M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-09 | $5.73M 10-Q · filed 2021-08-09 | $10.97M derived: sum of 3 quarters · filed 2022-03-01 | $11.14M derived: sum of 4 quarters · filed 2022-03-01 | ||||
| 2020-03-31 | -$6.33M 10-Q · filed 2021-05-11 | -$1.08M derived: sum of 2 quarters · filed 2022-03-01 | -$911.00K derived: sum of 3 quarters · filed 2022-03-01 | $840.00K derived: sum of 4 quarters · filed 2022-03-01 | ||||
| 2019-12-31 | $5.24M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $5.41M derived: sum of 2 quarters · filed 2022-03-01 | $7.17M derived: sum of 3 quarters · filed 2022-03-01 | $4.69M 10-K · filed 2022-03-01 | ||||
| 2019-09-30 | $170.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09 | $1.92M derived: sum of 2 quarters · filed 2020-11-09 | -$553.00K 10-Q · filed 2020-11-09 | $5.74M derived: sum of 4 quarters · filed 2021-03-16 | ||||
| 2019-06-30 | $1.75M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-10 | -$723.00K 10-Q · filed 2020-08-10 | $5.57M derived: sum of 3 quarters · filed 2021-03-16 | $11.73M derived: sum of 4 quarters · filed 2021-03-16 | ||||
| 2019-03-31 | -$2.47M 10-Q · filed 2020-05-11 | $3.82M derived: sum of 2 quarters · filed 2021-03-16 | $9.98M derived: sum of 3 quarters · filed 2021-03-16 | $12.18M derived: sum of 4 quarters · filed 2021-03-16 | ||||
| 2018-12-31 | $6.29M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-16 | $12.45M derived: sum of 2 quarters · filed 2021-03-16 | $14.66M derived: sum of 3 quarters · filed 2021-03-16 | $7.11M 10-K · filed 2021-03-16 | ||||
| 2018-09-30 | $6.16M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12 | $8.36M derived: sum of 2 quarters · filed 2019-11-12 | $815.00K 10-Q · filed 2019-11-12 | |||||
| 2018-06-30 | $2.21M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-09 | -$5.34M 10-Q · filed 2019-08-09 | ||||||
| 2018-03-31 | -$7.55M 10-Q · filed 2019-05-10 | |||||||
| 2017-12-31 | $7.01M 10-K · filed 2020-03-09 | |||||||
| 2016-12-31 | $6.56M 10-K · filed 2019-03-18 | |||||||
| 2016-03-31 | $241.00 10-Q · filed 2017-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 | |
| LIFECORE BIOMEDICAL, INC. DE (LFCR) | United States | $0.163B | -8.50 |